Honored to present in the S14 Session: New approaches in clinical particle radiotherapy chaired by @simonpowell213 + Armin Luehr (although I guess the slide deck turned out to be more preclinical)
Tough competition with S13: Immunotherapy RT combinations
#RadRes2020

#protontherapy has been for the longest time defined by its physical properties. It's time to think about its use in terms of biological properties, both in terms of tumor kill + toxicity.
We also need to get away from the "one-size-fits'all" thinking that permeates #radonc

So, can #protontherapy be used specifically on radioresistant tumors? We have lots of emerging biomarkers to guide #radiotherapy. Yesterday @max_diehn elegantly reviewed the radioresistance phenotype of KEAP1 mut cancers. In the talk I summarize data on KRAS.
#Radres2020

Another emerging opportunity for protons is its use in homologous recombination deficient tumors for which there is accumulating in vitro and in vivo evidence.
This means the RBE would be >> 1.1 in these cancers.
This has been understudied.
#RadRes2020

Basically, homologous recombination and other repair defects are hypothesized to amplify the consequences of clustered DNA damage between protons and standard radiation.
#RadRes2020

Lab data on enhanced proton sensitivity of cancer cells with HR of FA defects look pretty compelling. How will we translate this? We need biomarkers. Genomic or functional (foci!).
Biologically guided #protontherapy may change the debate of its benefits considerably!
#Radres2020